NICE has issued new final draft guidance recommending two new treatments for advanced malignant melanoma.
Ipilimumab is recommended for the treatment of advanced malignant melanoma in people who have received prior chemotherapy and Vemurafenib is recommended for the treatment of unresectable locally advanced or metastatic BRAF V600 mutation-positive melanoma. Both treatments are recommended on the basis that the manufacturers provide them with a discount, as agreed in separate patient access schemes for each appraisal.
